We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Inversago Pharma reeled in a $7 million series A round to move a suite of next-generation cannabinoid receptor-1 (CB1) blockers into the clinic. The Montreal-based startup is developing the drugs for Prader-Willi syndrome, as well as metabolic disorders i